| 放射治疗联合替莫唑胺治疗脑转移瘤的疗效分析 |
| |
| 引用本文： | 韦 燕,赵善琳,易海振,曾俊韶. 放射治疗联合替莫唑胺治疗脑转移瘤的疗效分析[J]. 现代肿瘤医学, 2015, 0(15): 2114-2116. DOI: 10.3969/j.issn.1672-4992.2015.15.08 |
| |
| 作者姓名： | 韦 燕 赵善琳 易海振 曾俊韶 |
| |
| 作者单位： | 广西医科大学附属第八医院（贵港市人民医院）肿瘤科，广西 贵港 537100 |
| |
| 基金项目： | 贵港市科学研究与技术开发计划项目（编号:贵科攻1305016） |
| |
| 摘 要： | 目的:观察放射治疗联合替莫唑胺治疗脑转移瘤患者的疗效。方法:将62名脑转移瘤患者随机分为放疗组和放疗联合替莫唑胺组。其中放疗组给予全脑照射，采用6MV－X线常规照射，2Gy/次，5次/周，共4周，总量40Gy，全脑放疗后，只对最大的2个病灶缩野加量至50-56Gy。放疗联合替莫唑胺组中，放射治疗方法同放疗组，并在放疗的整个疗程中同步口服替莫唑胺75mg/m2化疗至放疗结束。放疗结束后4周，继续使用替莫唑胺化疗，其中第1周期给量150mg/m2，连续用药5天，28天为一个疗程，若患者耐受良好，在以后化疗疗程中增量至200mg/m2，替莫唑胺推荐化疗6个周期。结果:放疗联合替莫唑胺组的有效率为83.9%，高于放疗组的71.0%（P>0.05）。中位生存期和1年生存率分别为14个月和58.1%，均高于放疗组的10个月和32.3%（P<0.05）。放疗联合替莫唑胺组的疾病控制率为93.6%，优于放疗组的90.3%。两组患者均未出现严重的不良反应。结论:替莫唑胺联合放疗在脑转移瘤的治疗中有较好的疗效和安全性。
|
| 关 键 词： | 替莫唑胺 放射治疗 脑转移瘤 |
Radiotherapy plus concomitant and adjuvant temozolomide for brain metastatic tumor |
| |
| Wei Yan,Zhao Shanlin,Yi Haizhen,Zeng Junshao. Radiotherapy plus concomitant and adjuvant temozolomide for brain metastatic tumor[J]. Journal of Modern Oncology, 2015, 0(15): 2114-2116. DOI: 10.3969/j.issn.1672-4992.2015.15.08 |
| |
| Authors: | Wei Yan Zhao Shanlin Yi Haizhen Zeng Junshao |
| |
| Affiliation: | Department of Medical Oncology，Guigang People's Hospital，Guangxi Guigang 537100,China. |
| |
| Abstract: | Objective:To observe the efficacy of temozolomide combined with radiotherapy for patients with brain metastasis.Methods:All 62 patients with brain metastasis were divided into temozolomide combined with radiotherapy group and radiotherapy group randomly.Radiotherapy group was given atotal dose of 40Gy，2Gy/t，5d/week of whole brain reirradiation.Extra dose of 50-56Gy with 3D-CRT technology would add to the 2 of the biggest nidus without incomplete regression after accepting dose of 40Gy.Patients in temozolomide combined with radiotherapy group received irradiation at the same dose plus concomitant daily temozolomide administered orally at a dose of 75mg/m2，and completion of radiation therapy took 150mg/(m2·d) at first cycle (5 days every 28 days for one cycles)，200mg/(m2·d) at second to the sixth cycles.Results:The efficiency rate of temozolomide combined with radiotherapy group was 83.9% and the radiotherapy group was 71.0%(P>0.05），mean survival time，one-year survival rate and disease control rate in temozolomide combined with radiotherapy group was 14 months,58.1% and 93.6%，significantly higher than that in radiotherapy group (P<0.05）.No significant adverse reactions appeared in two groups.Conclusion:Radiotherapy plus temozolomide for the treatment of patients with brain metastasis is effective and safe. |
| |
| Keywords: | temozolomide radiotherapy brain metastasis |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
